POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report no. 17 / 2020

Date of preparation: 2020-03-16

Abbreviated name of the Issuer:
MABION S.A.

Subject matter:
Information on the impact of the COVID-19 spread on the Company's activities

Legal basis:
Article 17(1) MAR – confidential information.

Content of the report:

In connection with the epidemic emergency introduced in Poland and the COVID-19 coronavirus pandemic announced by WHO (World Health Organization) the Management Board of Mabion S.A. ("Issuer"), "(Company") provides information on the possible impact of this situation on the Issuer's operations.

In the current situation, the Management Board is of the opinion that the Issuer's operations may be temporarily affected by reduced availability of employees and, as a consequence, delays in research and development processes, due to the need to introduce home office work for certain positions.

The Management Board emphasises that it has a certain degree of control over the pace and continuity of the manufacturing processes, but it cannot be ruled out that the introduction of remote work in certain positions and potential disturbances in the integrity of the supply chain of certain components, materials, and machinery and equipment will temporarily slow down R&D and production processes, including the production of the last of the three planned Mabion CD20 large-scale validation batches.

At the same time, the Company's Management Board points out that the Company's processes are focused on maintaining progress and completing work on the Mabion CD20 validation, which will enable the Company to proceed to the next stages of research and development of the medicinal product manufactured as part of large-scale production (i.e. stability and analytical similarity studies). The Management Board informs that at the moment of submitting this report, the work in consideration is progressing smoothly, in line with the planned schedules, and the Management Board is not aware of any delays in supply of components, materials, or machinery or equipment. However, it cannot be excluded that such delays will occur in the future.

The Company's Management Board also recognizes the risks associated with the liquidity disruption in the markets resulting from the spread of COVID-19 and the consequent possible restriction of the Company's access to finance. Furthermore, it draws attention to potential shifts in administrative processes, including both in the area of decisions of authorities regulating the market authorisation of medicinal products and in the area of decisions of public authorities awarding and settling subsidies and grants or VAT refunds. The Management Board emphasises that at the time of submitting this current

report, it did not receive any information from the above-mentioned authorities concerning any shift in the processes in progress.

The persisting pandemic, including, among others, the reduction of passenger traffic may also contribute to the temporary need of reducing the Company's marketing activity in the area of business development, as well as the suspension of key business decisions as part of the talks conducted.

Due to the dynamics of events, the Issuer's Management Board monitors the situation on an ongoing basis. In the case of material new circumstances related to the COVID-19 pandemic and affecting the Issuer's business, the Company will provide relevant current reports. At the same time, the Issuer declares that it will comply with all applicable administrative decisions.

More detailed information on the impact of COVID-19 on the Issuer's business and financial condition will be included by the Company in the annual report for 2019 (publication date: April 9th, 2020) and possibly in subsequent interim reports.